A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Inclusion criteria

• Female or male patients ≥18 years old；
• Biopsy-confirmed primary IgA nephropathy；
• Urine protein≥0.75 g/24hr or urine protein creatinine ratio (UPCR)≥0.5 g/g；
• Estimated GFR (using the CKD-EPI2009 formula) ≥30mL/min/1.73 m2；
• Willing and able to take adequate contraception during the trial;
• Willing and able to give informed consent and follow the protocols during the trial.

Exclusion criteria

• Systemic diseases which could lead to secondary IgA nephropathy；
• Patients with severe chronic infection or active infection under systemic antibiotic therapy in previous 14 days；
• Patients with severe cardiovascular diseases；
• Patients diagnosed with malignancy within the past 5 years；
• Patients with liver cirrhosis；
• Patients received organ transplantation；
• Patients with uncontrolled Type 1 or 2 diabetes；
• Positive results in HIV-Ab/TP-Ab/ HBsAg/HCV-Ab tests；
• Patients treated with any systemic immunosuppressive drugs (excluding corticosteroids) within the past 12 months before screening；
• Patients treated with any systemic corticosteroids within the past 3 months before screening.